{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:27:27Z","timestamp":1792902447676,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00441289"],"award-info":[{"award-number":["RS-2024-00441289"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00512586"],"award-info":[{"award-number":["RS-2025-00512586"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118691","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T02:21:54Z","timestamp":1761790914000},"page":"118691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CliCAR: A non-genetic CAR engineering strategy to empower NK cells for targeted cancer immunotherapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Su Yeon","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeongbeom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ouk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Jin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ann","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehyun","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-6260","authenticated-orcid":false,"given":"Young-Wook","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-8788","authenticated-orcid":false,"given":"Kwang Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118691_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cvsm.2023.12.002","article-title":"Cancer immunotherapy","volume":"54","author":"Bergman","year":"2024","journal-title":"Vet. Clin. North Am. Small Anim. Pr."},{"issue":"3","key":"10.1016\/j.biopha.2025.118691_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Pt 2","key":"10.1016\/j.biopha.2025.118691_bib3","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"17","key":"10.1016\/j.biopha.2025.118691_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2025.118691_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.biopha.2025.118691_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118691_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells13050451","article-title":"Building a better defense: expanding and improving natural killer cells for adoptive cell therapy","volume":"13","author":"Maia","year":"2024","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.biopha.2025.118691_bib8","first-page":"1800447","article-title":"One-Step method for instant generation of advanced allogeneic NK cells","volume":"5","author":"Lee","year":"2018","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.biopha.2025.118691_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118245","article-title":"Advanced breast cancer immunotherapy: surface modification of NK cells for embedding antibody-drug conjugates","volume":"189","author":"Lim","year":"2025","journal-title":"Biomed. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2025.118691_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091189","article-title":"Synergistic Chemo-Immunotherapy: recombinant fusion Protein-Based surface modification of NK cell for targeted cancer treatment","volume":"16","author":"Lim","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7949","key":"10.1016\/j.biopha.2025.118691_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.118691_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","article-title":"A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma","volume":"78","author":"Ratto","year":"1996","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.biopha.2025.118691_bib13","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/cancers17142397","article-title":"Engineering innate immunity: recent advances and future directions for CAR-NK and CAR\u2013Macrophage therapies in solid tumors","volume":"17","author":"Amoozgar","year":"2025","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.biopha.2025.118691_bib14","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR t cells","volume":"24","author":"Velasco Cardenas","year":"2023","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118691_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142030","article-title":"Insight into next-generation CAR therapeutics: designing CAR t cells to improve clinical outcomes","volume":"131","author":"Roselli","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010204","article-title":"The evolving protein engineering in the design of chimeric antigen receptor t cells","volume":"21","author":"Hughes-Parry","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118691_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"issue":"10","key":"10.1016\/j.biopha.2025.118691_bib19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118691_bib20","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR t and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118691_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.biopha.2025.118691_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived natural killer cells engineered with chimeric antigen receptors enhance Anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118691_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118691_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221118413","article-title":"Relapse mechanism and treatment strategy after chimeric antigen receptor T-Cell therapy in treating B-Cell hematological malignancies","volume":"21","author":"Xie","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.biopha.2025.118691_bib27","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Naeimi Kararoudi","year":"2022","journal-title":"Cell Rep. Methods"},{"issue":"5","key":"10.1016\/j.biopha.2025.118691_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050732","article-title":"Host cell restriction factors blocking efficient vector transduction: challenges in lentiviral and Adeno-Associated vector based gene therapies","volume":"12","author":"Coroadinha","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.biopha.2025.118691_bib29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jcyt.2021.04.010","article-title":"Transient blockade of TBK1\/IKK\u03b5 allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors","volume":"23","author":"Chockley","year":"2021","journal-title":"Cytotherapy"},{"issue":"15","key":"10.1016\/j.biopha.2025.118691_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512220","article-title":"Influenza a infection stimulates RIG-I and enhances effector function of primary human NK cells","volume":"24","author":"Mohamed","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118691_bib31","article-title":"Innate sensing of viral nucleic acids and their use in antiviral vaccine development","volume":"13","author":"Enya","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41467-023-35844-2","article-title":"TLR3 forms a laterally aligned multimeric complex along double-stranded RNA for efficient signal transduction","volume":"14","author":"Sakaniwa","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib33","doi-asserted-by":"crossref","first-page":"9871","DOI":"10.1038\/s41467-024-54232-y","article-title":"Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation","volume":"15","author":"McCulloch","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2025.118691_bib34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.4049\/jimmunol.2300731","article-title":"NK Cell-Monocyte Cross-talk underlies NK cell activation in severe COVID-19","volume":"212","author":"Lee","year":"2024","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118691_bib35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4014\/jmb.2304.04023","article-title":"Role of Interleukin(IL)-6 in NK activity to Hypoxic-Induced highly invasive hepatocellular Carcinoma(HCC) cells","volume":"33","author":"Lee","year":"2023","journal-title":"J. Microbiol. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"Jorgensen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118691_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","article-title":"Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","volume":"20","author":"Allan","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118691_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009560","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118691_bib39","article-title":"Natural killer cell membrane manipulation for augmented immune synapse and anticancer efficacy","volume":"33","author":"Ryu","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biopha.2025.118691_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108212","article-title":"Non-viral engineering of NK cells","volume":"68","author":"Hinnekens","year":"2023","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib41","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041250","article-title":"Mechanism of protein translocation by the Sec61 translocon complex","volume":"15","author":"Itskanov","year":"2023","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118691_bib42","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","article-title":"Universal redirection of CAR t cells against solid tumours via membrane-inserted ligands for the CAR","volume":"7","author":"Zhang","year":"2023","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.biopha.2025.118691_bib43","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","article-title":"A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced t lymphocytes and antitumor activity","volume":"183","author":"Zhao","year":"2009","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118691_bib44","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2025.118691_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.512","article-title":"Production of eukaryotic glycoproteins for structural and functional studies using Expi293F cells","volume":"2","author":"Greven","year":"2022","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.biopha.2025.118691_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-0716-1406-8_5","article-title":"Transient transfection and expression of eukaryotic membrane proteins in Expi293F cells and their screening on a small scale: application for structural studies","volume":"2305","author":"Krasnoselska","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin v","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.biopha.2025.118691_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharm."},{"issue":"17","key":"10.1016\/j.biopha.2025.118691_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300236","article-title":"Cell penetrating peptides: classification, mechanisms, methods of study, and applications","volume":"18","author":"Gori","year":"2023","journal-title":"ChemMedChem"},{"issue":"18","key":"10.1016\/j.biopha.2025.118691_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cells12182312","article-title":"The chemical inhibitors of endocytosis: from mechanisms to potential clinical applications","volume":"12","author":"Szewczyk-Roszczenko","year":"2023","journal-title":"Cells"},{"issue":"31","key":"10.1016\/j.biopha.2025.118691_bib51","doi-asserted-by":"crossref","first-page":"51037","DOI":"10.18632\/oncotarget.17558","article-title":"Structural basis of a novel heterodimeric fc for bispecific antibody production","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118691_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.mcb.2021.08.002","article-title":"Evaluation of CAR-T cell cytotoxicity: real-time impedance-based analysis","volume":"167","author":"Lisby","year":"2022","journal-title":"Methods Cell Biol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118691_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2025.118691_bib54","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.7150\/thno.79942","article-title":"Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity","volume":"13","author":"Shin","year":"2023","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib55","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","article-title":"\"UniCAR\"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells","volume":"10","author":"Mitwasi","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118691_bib56","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jtho.2023.12.019","article-title":"Prevalence and therapeutic targeting of High-Level ERBB2 amplification in NSCLC","volume":"19","author":"Odintsov","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib57","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118691_bib58","doi-asserted-by":"crossref","first-page":"1509980","DOI":"10.3389\/fimmu.2024.1509980","article-title":"The impact of CD3zeta ITAM multiplicity and sequence on CAR T-cell survival and function","volume":"15","author":"Majumdar","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib59","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1038\/s41467-024-51039-9","article-title":"3D live imaging and phenotyping of CAR-T cell mediated-cytotoxicity using high-throughput bessel oblique plane microscopy","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2025.118691_bib60","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR t cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118691_bib61","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49023","article-title":"Deep-learning-based three-dimensional label-free tracking and analysis of immunological synapses of CAR-T cells","volume":"9","author":"Lee","year":"2020","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.biopha.2025.118691_bib62","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ymthe.2024.04.027","article-title":"Controlling CAR-T cell activity and specificity with synthetic SparX adapters","volume":"32","author":"Edwards","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-cancerbio-070220-111016","article-title":"Central role of the antigen-presentation and interferon-\u03b3 pathways in resistance to immune checkpoint blockade","volume":"6","author":"Paschen","year":"2022","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000291","article-title":"Granzyme b PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response","volume":"8","author":"LaSalle","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7757","key":"10.1016\/j.biopha.2025.118691_bib65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118691_bib66","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","article-title":"Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity","volume":"16","author":"Kiesgen","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2025.118691_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a Double-Edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118691_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.158","article-title":"Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer","volume":"8","author":"Shen","year":"2017","journal-title":"Cell Death Dis."},{"issue":"39","key":"10.1016\/j.biopha.2025.118691_bib69","doi-asserted-by":"crossref","first-page":"65743","DOI":"10.18632\/oncotarget.19445","article-title":"Resveratrol promotes MICA\/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc\/miR-17 pathway","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biopha.2025.118691_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib71","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41467-024-44688-3","article-title":"LFA-1 nanoclusters integrate TCR stimulation strength to tune T-cell cytotoxic activity","volume":"15","author":"Lacouture","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib72","article-title":"Single-Cells isolation and molecular analysis: focus on HER2-Low CTCs in metastatic breast cancer","volume":"14","author":"D'Amico","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6534","key":"10.1016\/j.biopha.2025.118691_bib73","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.biopha.2025.118691_bib74","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol."},{"issue":"39","key":"10.1016\/j.biopha.2025.118691_bib75","doi-asserted-by":"crossref","first-page":"eabo0514","DOI":"10.1126\/sciadv.abo0514","article-title":"CAR density influences antitumoral efficacy of BCMA CAR t cells and correlates with clinical outcome","volume":"8","author":"Rodriguez-Marquez","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2025.118691_bib76","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s42003-020-1021-2","article-title":"convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting","volume":"3","author":"Landgraf","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.biopha.2025.118691_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of CD123-Positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:51:45Z","timestamp":1777013505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":77,"alternative-id":["S0753332225008856"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118691","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CliCAR: A non-genetic CAR engineering strategy to empower NK cells for targeted cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118691"}}